| Literature DB >> 23409083 |
Bo Zhang1, Lin Zhang, Ruixue Dai, Meiying Yu, Guoping Zhao, Xiaoming Ding.
Abstract
Streptomyces bacteria are known for producing important natural compounds by secondary metabolism, especially antibiotics with novel biological activities. Functional studies of antibiotic-biosynthesizing gene clusters are generally through homologous genomic recombination by gene-targeting vectors. Here, we present a rapid and efficient method for construction of gene-targeting vectors. This approach is based on Streptomyces phage φBT1 integrase-mediated multisite in vitro site-specific recombination. Four 'entry clones' were assembled into a circular plasmid to generate the destination gene-targeting vector by a one-step reaction. The four 'entry clones' contained two clones of the upstream and downstream flanks of the target gene, a selectable marker and an E. coli-Streptomyces shuttle vector. After targeted modification of the genome, the selectable markers were removed by φC31 integrase-mediated in vivo site-specific recombination between pre-placed attB and attP sites. Using this method, part of the calcium-dependent antibiotic (CDA) and actinorhodin (Act) biosynthetic gene clusters were deleted, and the rrdA encoding RrdA, a negative regulator of Red production, was also deleted. The final prodiginine production of the engineered strain was over five times that of the wild-type strain. This straightforward φBT1 and φC31 integrase-based strategy provides an alternative approach for rapid gene-targeting vector construction and marker removal in streptomycetes.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23409083 PMCID: PMC3567011 DOI: 10.1371/journal.pone.0055906
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Strains and plasmids used in this study.
| Strains or plasmids | Genotype or description | Ref. or source |
|
| ||
| M145 | SCP1- SCP2- |
|
| ZB1 | M145 with CDA gene cluster disrupted, containing | This work |
| ZB2 | ZB1 with the resistance gene removed | This work |
| ZB3 | ZB2 with Act gene cluster disrupted, containing a | This work |
| ZB4 | ZB3 with the resistance gene removed | This work |
| ZB7 | ZB4 with | This work |
| ZB8 | ZB7 with the resistance gene removed | This work |
| ZB8/pFDZ16- | ZB8 carrying integrative plasmid pFDZ16- | This work |
| ZB8/pFDZ16 | ZB8 carrying integrative plasmid pFDZ16 | This work |
|
| ||
| DH5α | F- |
|
| ET12567 |
|
|
|
| ||
| pMD19-T | 2.7-kb cloning vector; Ampr | Takara |
| pBC-AM | Donor of |
|
| pHZ1358 |
|
|
| pXD34-int |
| This work |
| pFDZ100 |
| This work |
| pTA0006 | Derivative obtained from pMD19-T, containing |
|
| pTA0613 | Derivative obtained from pMD19-T, containing |
|
| pTA1315 | Derivative obtained from pMD19-T, containing | This work |
| pFDZ101 | Derivative obtained from pTA0006, containing | This work |
| pFDZ102 | Derivative obtained from pTA0613, replacing the | This work |
| pFDZ103 | Derivative obtained from pTA1315, containing | This work |
| pFDZ101-CDA-5′arm | Derivative obtained from pFDZ101, containing upstream homologous arm of CDA biosynthetic gene cluster gene-targeting | This work |
| pFDZ103-CDA-3′arm | Derivative obtained from pFDZ103, containing downstream homologous arm of CDA biosynthetic gene cluster gene-targeting | This work |
| pFDZ101-Act-5′arm | Derivative obtained from pFDZ101, containing upstream homologous arm of Act biosynthetic gene cluster gene-targeting | This work |
| pFDZ103-Act-3′arm | Derivative obtained from pFDZ103, containing downstream homologous arm of Act biosynthetic gene cluster gene-targeting | This work |
| pFDZ101- | Derivative obtained from pFDZ101, containing upstream homologous arm of | This work |
| pFDZ103- | Derivative obtained from pFDZ103, containing downstream homologous arm of | This work |
| pFDZ100-CDA-tandem | Derivative obtained from pFDZ100, containing two homologous arms of CDA biosynthetic gene cluster gene-targeting; Aprar | This work |
| pFDZ100-Act-tandem | Derivative obtained from pFDZ100, containing two homologous arms of Act biosynthetic gene cluster gene-targeting; Kanr | This work |
| pFDZ100- | Derivative obtained from pFDZ100, containing two homologous arms of | This work |
| pZB101 |
| This work |
| pZB102 |
| This work |
| pSET152 | Integrative vector for actinomycetes; containing |
|
| pRT802 |
|
|
| pFDZ16 |
|
|
| pFDZ16- | Derivative obtained from pFDZ16, containing the |
|
Figure 1Map of four ‘entry vectors’ used in this study.
Plasmids pFDZ101 and pFDZ103 were used to harbor the 5′-arm and 3′-arm respectively, and pFDZ102 contained the selectable marker (aphII gene). pFDZ100 was the backbone of the gene-targeting vector. Each vector contained a pair of non-compatible recombination φBT1 integration sites (arrows in green). The pink arrows represent the recombination φC31 integration sites, where recombination occurred to remove the marker gene.
Figure 2Strategy of tandem assembly in vitro and the marker removing in vivo based on site-specific recombinations.
(A) One step assembly of the gene-targeting vector by φBT1 integrase-mediated site-specific recombination in vitro. Four recombination reactions occurred simultaneously between attB and attB. (B) Deletion of marker by φC31 integrase-mediated site-specific recombination in vivo. The reaction occurred between attB-φC31 and attP-φC31 to remove the marker and leave attL-φC31.
Figure 3PCR analysis and phenotypes of mutants.
(A) PCR verification of gene deletion. Lane 1, a 42,725 bp fragment was amplified using primers ZB287/ZB288. The size of the fragment was too large and could not be PCR-amplified, thus no band was seen in lane 1. Lane 2, a 1981 bp fragment was amplified using primers ZB287/ZB288. The CDA biosynthetic gene cluster was replaced with the aac(3)IV gene. Lane3, a 927 bp fragment was amplified using primers ZB287/ZB288, and the resistance gene was removed. Lane 4, a 4073 bp fragment was amplified with primers ZB289/ZB290. Lanes 5 and 6 showed the bands before and after removing the aphII resistance gene. Lane 7, a 928 bp fragment was amplified with primers ZB285/ZB286. Lanes 8 and 9 showed thebands before and after removing the aphII resistance gene. WT, wild type strain; ZB1∼ZB8, serial mutant strains. (B) PCR verification of gene deletion. Lane 1: the fragment was amplified with primers ZB145/ZB146 and primers were both within sco3229. Lane 2: the fragment was amplified with primers ZB195/ZB196 and primerZB195 was within sco5089 and primer ZB196 was within sco5090. Lane 3: the fragment was amplified with primers ZB184/ZB186 and primerZB184 was within sco1103 and primer ZB184 was within sco1104. Lane 4: the fragment as a positive control was amplified with primers ZB147/ZB148 and primers were both within sco5888. M: 150 bp ladder. (C) PCR verification of the resistance removing. Lane 1: M145; Lane 2: ZB1; Lane 3: ZB2. The three fragments were amplified with primers ZB189/ZB190, primers were both within the acc(3)IV gene. Lane 4: M 145; Lane 5: ZB3; Lane 6: ZB4; Lane 7: ZB7; Lane 8: ZB8. The five fragments were amplified with primers ZB187/ZB188, primers were both within the aphII gene. M: 150 bp ladder. (D) Bioassay of CDA extracts from the WT strain and CDA-null mutant strain ZB2. (E) Phenotypes of wild-type and three mutant strains. The spores were cultured for 2 days (left) and 5 days (right) on R2YE agar.
Figure 4Growth curves and prodiginine production of wild-type strain, three mutant strains and complemented strains.
Growth curves (A) and prodiginine production (B) of M145, ZB2, ZB4, ZB8, ZB8/pFDZ16 and ZB8/pFDZ16-rrdA growth in 40 ml of R4 liquid medium. Incubation was carried out at 30°C. The symbols indicate the averages of three independent determinations and the error bars indicate the standard errors. OD530, optical density at 530 nm.